C9orf131

Across TCGA pan-cancer cohorts, C9orf131 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C9orf131 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher C9orf131 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C9orf131 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, MESO, and LIHC are the cancer types where C9orf131 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.124	0.712	<.001	48	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	12	view →
UCEC	OS	Median	All	0.973	0.864	.040	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C9orf131–HNSC (DFS)

Open the HNSC breakdown →